{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/","result":{"pageContext":{"chapter":{"id":"19b6008a-dd02-5fdb-b146-5cb427bb1f29","slug":"hormone-replacement-therapy-hrt","fullItemName":"Hormone replacement therapy (HRT)","depth":2,"htmlHeader":"<!-- begin field c2dab65d-ef7e-41f2-ba57-4305fc948e59 --><h2>Hormone replacement therapy (HRT)</h2><!-- end field c2dab65d-ef7e-41f2-ba57-4305fc948e59 -->","summary":"","htmlStringContent":"<!-- begin item 1a61df54-8f85-4f4a-8ae8-979b75562ab3 --><!-- end item 1a61df54-8f85-4f4a-8ae8-979b75562ab3 -->","topic":{"id":"69003588-b736-585d-8a5d-7ca0e916caa5","topicId":"f75fa6a7-10c6-4887-9cf1-3ea14d7f353c","topicName":"Menopause","slug":"menopause","lastRevised":"Last revised in November 2020","chapters":[{"id":"0359e5fa-1342-5767-a4da-2f8b5cd2b6db","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c978ff88-dda8-5879-a0ac-9b09182d81d1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d381eed9-6611-5263-a3be-b46ec9f02058","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ddcba55c-566e-5433-8dce-2e5f5cee0ba4","slug":"changes","fullItemName":"Changes"},{"id":"e521b2f5-34d4-580f-b63d-a1ec2d0c13a3","slug":"update","fullItemName":"Update"}]},{"id":"ab5690cf-81b4-5fa9-b69f-27abc2e034a3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c0f45ff8-442c-5027-922e-12d108200960","slug":"goals","fullItemName":"Goals"},{"id":"8459ae09-bdf2-5d0d-9728-538e93d05a8f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"43027e52-84ef-53fa-88c5-a84289154e48","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4620ee3c-97ae-5f9f-8bac-fc8497801cdb","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b26fb3cf-562a-595a-8f9e-92fd752d2e6b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"10c1cb80-22cc-5889-8e30-35cf1a9843bf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"18c173af-ec8a-571c-be49-d894f0bec50b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8e86f5f5-2343-5ea3-8d0d-7dda791a066e","slug":"definition","fullItemName":"Definition"},{"id":"17295b39-3f33-5e75-8d8a-1fc32c2efb70","slug":"causes","fullItemName":"Causes"},{"id":"5b768dab-f7db-50c3-8686-0d363f36e74d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"698848d3-f122-5e5a-acc8-98518854f51b","slug":"complications","fullItemName":"Complications"},{"id":"647a928d-775d-5b0b-b577-b695140b26a3","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"00aeafb7-f9e4-5fd2-8fd2-57bd7fd333d8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d68ce2dd-2971-5c66-b22c-df0db848cf06","slug":"diagnosis-of-menopause-perimenopause","fullItemName":"Diagnosis of menopause and perimenopause"},{"id":"8b9c8208-91c2-5751-8a76-dc9461736050","slug":"diagnosis-of-premature-ovarian-insufficiency","fullItemName":"Diagnosis of premature ovarian insufficiency"},{"id":"a84016e1-b7af-55f9-b1f8-c85ff76cfc93","slug":"assessment","fullItemName":"Assessment"},{"id":"6c51a87c-f89c-5e58-b495-39506bc70e62","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"649507f8-7b95-5740-9833-fee7c5bff092","fullItemName":"Management","slug":"management","subChapters":[{"id":"9c13d541-f2ee-5d0a-a174-cd7c7b4aa392","slug":"management-of-menopause-perimenopause-or-premature-ovarian-insufficiency","fullItemName":"Scenario: Management of menopause, perimenopause, or premature ovarian insufficiency"}]},{"id":"7d937659-3134-52f9-8742-b90a6ffb1f1f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"19b6008a-dd02-5fdb-b146-5cb427bb1f29","slug":"hormone-replacement-therapy-hrt","fullItemName":"Hormone replacement therapy (HRT)"}]},{"id":"ff6b5c36-2033-50a7-9c74-c9e46f1c8242","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c9280136-8c1b-5890-96e2-c8f14078bb5f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4f9c2c0d-8ea0-5048-8ae4-0b2517bed5ca","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4b187b70-dcd7-5e05-ac85-fd75204e2515","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b3e44a7a-44e1-5dec-bd9e-67a0cad5baca","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6e1b4175-c43f-53ce-8884-b9f1b5b39f58","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e0d3a8f-c4c1-533c-b265-34d08681175b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e6340cdd-13d8-5fde-912f-a3d2c50f305f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7d937659-3134-52f9-8742-b90a6ffb1f1f","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"92d4950c-8f39-5890-a37b-64e628f5756e","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 9a71edc7-589c-46c1-942e-bbdf7c6a5e2a --><h3>Contraindications and cautions</h3><!-- end field 9a71edc7-589c-46c1-942e-bbdf7c6a5e2a -->","summary":"","htmlStringContent":"<!-- begin item b4fab161-7434-4025-aa9a-77a6c0024081 --><!-- begin field 77d3ca65-aeac-42c8-a4a3-1682168382ef --><ul><li><strong>Do not prescribe hormone replacement therapy (HRT) in women with:</strong><ul><li>Current, past, or suspected breast cancer.</li><li>Known or suspected oestrogen-dependent cancer.</li><li>Undiagnosed vaginal bleeding.</li><li>Untreated endometrial hyperplasia.</li><li>Previous idiopathic or current venous thromboembolism (deep vein thrombosis or pulmonary embolism), unless the woman is already on anticoagulant treatment.</li><li>Active or recent arterial thromboembolic disease (for example angina or myocardial infarction).</li><li>Active liver disease with abnormal liver function tests.</li><li>Pregnancy.</li><li>Thrombophilic disorder.</li></ul></li><li><strong>Prescribe HRT with caution in women with:</strong><ul><li>Porphyria cutanea tarda.</li><li>Diabetes mellitus (increased risk of heart disease).</li><li>Factors predisposing to venous thromboembolism.</li><li>History of endometrial hyperplasia.</li><li>Migraine and migraine-like headaches.</li><li>Increased risk of breast cancer. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/breast-cancer-managing-fh/\">Breast cancer - managing FH</a> for more information.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Goodman, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 77d3ca65-aeac-42c8-a4a3-1682168382ef --><!-- end item b4fab161-7434-4025-aa9a-77a6c0024081 -->","subChapters":[]},{"id":"f5204dd3-5a09-5450-b8c3-56eeab54fd07","slug":"route-of-administration","fullItemName":"Route of administration","depth":3,"htmlHeader":"<!-- begin field 2bda0623-466f-4de7-8388-0c51e18789b9 --><h3>Route of administration</h3><!-- end field 2bda0623-466f-4de7-8388-0c51e18789b9 -->","summary":"","htmlStringContent":"<!-- begin item e1dacb5d-c37b-4d0f-a079-be6fbaa21470 --><!-- begin field 2d3af138-0145-4fee-a7ba-f6e9876daefe --><ul><li><strong>Hormone replacement therapy (HRT) is available as oral or transdermal preparations,</strong> depending on the woman's preferences.<ul><li><strong> </strong>Oestrogen-only preparations are given to women without a uterus, and combined oestrogen and progestogen preparations are given to women with an intact uterus [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>].</li><li>Transdermal preparations may be appropriate if the woman has [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Anagnostis, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Ayres, 2020</a>]:<ul><li>Persistent troublesome symptoms with oral treatment.</li><li>Troublesome <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#adverse-effects\">adverse effects</a> with oral treatment.</li><li>A history of, or increased risk of, venous thromboembolism.</li><li>Cardiovascular risk factors, such as obesity, uncontrolled hypertension, or hypertriglyceridaemia. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a> for more information.</li><li>Concomitant hepatic enzyme-inducing drug treatment (for example carbamazepine).</li><li>A gastrointestinal disorder that may affect absorption of oral treatment.</li><li>A history of migraine or gallbladder disease.</li><li>Lactose sensitivity (most HRT oral preparations contain lactose).</li></ul></li><li>Transdermal preparations are available as a gel (oestrogen only), patch (oestrogen only or combined oestrogen and progestogen), or spray (oestrogen only) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Ayres, 2020</a>].<ul><li>If the woman is using combined HRT, the progestogen component may also be given separately as an oral tablet or as the levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena<sup>®</sup>).</li></ul></li></ul></li><li><strong>Low-dose vaginal oestrogen</strong> <strong>is available as</strong> a vaginal tablet (Vagifem®), creams (Ovestrin® or Gynest®), gel (Blissel®), pessary (Imvaggis®), and vaginal ring (Estring®), depending on the woman's preferences [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Ayres, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Joint Formulary Committee, 2020</a>].<ul><li>Note: a progestogen is not needed for endometrial protection, as systemic absorption of vaginal oestrogen is minimal.</li></ul></li></ul><!-- end field 2d3af138-0145-4fee-a7ba-f6e9876daefe --><!-- end item e1dacb5d-c37b-4d0f-a079-be6fbaa21470 -->","subChapters":[]},{"id":"3da95988-f048-58d5-afb7-0c86d9f45abe","slug":"choice-of-hormone","fullItemName":"Choice of hormone","depth":3,"htmlHeader":"<!-- begin field 98c1222a-56aa-44fc-a8ff-d7f7f45b6fdd --><h3>Choice of hormone</h3><!-- end field 98c1222a-56aa-44fc-a8ff-d7f7f45b6fdd -->","summary":"","htmlStringContent":"<!-- begin item 5be302a3-0bd3-44fc-b6b4-a8f358e76b4b --><!-- begin field 1366e29c-3167-43e9-8204-271a9cb36566 --><ul><li><strong>Choice of systemic oestrogen</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Rees, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Ayres, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Joint Formulary Committee, 2020</a>] <ul><li>'Natural' oestrogens are found in normal physiology (may be manufactured chemically, or extracted from a plant or animal source), such as conjugated oestrogen, estradiol, estrone, and estriol, and are generally used in systemic hormone replacement therapy (HRT) preparations.</li><li>'Synthetic' oestrogens, such as mestranol or ethinylestradiol, are generally not used, except in women with premature ovarian insufficiency (POI) in certain circumstances, due to their greater metabolic impact.</li></ul></li><li><strong>Choice of progestogen</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Rees, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Ayres, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stephens, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Joint Formulary Committee, 2020</a>]<ul><li>The progestogens most commonly used in combined oral HRT are almost all synthetic and include dydrogesterone, medroxyprogesterone, norethisterone, levonorgestrel, norgestrel, and drospirenone. Women vary in their tolerance to progestogens, and changing the progestogen component of combined HRT may be needed if progestogenic adverse effects occur:<ul><li>Combined HRT patches only contain norethisterone or levonorgestrel.</li><li>Medroxyprogesterone, dydrogesterone, and drospirenone may be better tolerated than norethisterone or levonorgestrel, because they are less androgenic.</li><li>Drospirenone also has aldosterone antagonistic activity and is useful for women who have fluid retention during the progestogen phase.</li><li>Micronized progesterone or dydrogesterone may be preferred in women with hypertriglyceridaemia due to their neutral effect on lipid profile [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Anagnostis, 2020</a>].</li></ul></li><li>The levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena<sup>®</sup>) is an alternative route of delivery of progestogen, which provides endometrial protection locally, resulting in low systemic levels of levonorgestrel. It may be useful in women:<br><ul><li>With persistent progestogenic <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#adverse-effects\">adverse effects</a> from systemic HRT.</li><li>With troublesome or heavy withdrawal bleeds taking <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#regimen\">cyclical</a> HRT.</li><li>Contraception is needed along with HRT. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#information-lifestyle-advice\">Information and lifestyle advice</a> for more information.</li><li>Note: women may use a Mirena® levonorgestrel-releasing intrauterine system (LNG-IUS) with oestrogen for up to 5 years for endometrial protection, as part of an HRT regimen (licensed for 4 years but may be used for up to 5 years off-label). Women using Mirena® for this purpose must have the device changed every 5 years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">FSRH, 2019</a>].</li></ul></li></ul></li><li><strong>Combined oestrogen/bazedoxifene acetate</strong> (a selective estrogen receptor modulator) oral preparation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Joint Formulary Committee, 2020</a>]<ul><li>This may be an option for women with a uterus (with at least 12 months since the last menstrual period), if progestogen-containing therapy is not appropriate. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#adverse-effects\">Adverse effects</a> for more information.</li></ul></li></ul><!-- end field 1366e29c-3167-43e9-8204-271a9cb36566 --><!-- end item 5be302a3-0bd3-44fc-b6b4-a8f358e76b4b -->","subChapters":[]},{"id":"c6a12db2-c860-51c7-8e7a-3f59f8532a9f","slug":"regimen","fullItemName":"Regimen","depth":3,"htmlHeader":"<!-- begin field 0fdd6027-5b61-4089-83d4-e47a380056eb --><h3>Regimen</h3><!-- end field 0fdd6027-5b61-4089-83d4-e47a380056eb -->","summary":"","htmlStringContent":"<!-- begin item e0ea5cee-1ae5-4979-83d9-5f32d29dfa32 --><!-- begin field 9abe46d5-c907-418b-9054-5a8613bf23ce --><ul><li><strong>The hormone replacement therapy (HRT) regimen used depends on</strong> whether the woman is perimenopausal, postmenopausal, the route of adminstration, and the woman's wishes.<br><ul><li><strong>Combined HRT can be prescribed as a:</strong><ul><li>Monthly cyclical regimen — oestrogen is taken daily and progestogen is given at the end of the cycle for 10–14 days.</li><li>Three-monthly cyclical regimen — oestrogen is taken daily and progestogen is given for 14 days every 13 weeks.</li><li>Continuous combined regimen — oestrogen and progestogen are taken daily.</li></ul></li><li><strong>For perimenopausal women, </strong>monthly or 3-monthly cyclical regimens may be used.<ul><li>A 3-monthly regimen may be more suitable for women with infrequent periods or who are intolerant to progestogens. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#adverse-effects\">adverse effects</a> for more information.</li><li>A monthly regimen produces monthly bleeding whilst a 3-monthly regimen produces a bleed every 3 months.</li><li>A continuous combined regimen is not suitable for use in the perimenopause or within 12 months of the last menstrual period.</li><li>Note: the absence of bleeding whilst taking a cyclical regimen reflects an atrophic endometrium.<ul><li>Exclude pregnancy in perimenopausal women or women with premature ovarian insufficiency.</li><li>Check compliance with therapy if the progestogen component is taken separately.</li></ul></li><li>If HRT was initiated in the perimenopause, consideration should be given to switching from monthly or 3-monthly cyclical regimens to continuous combined regimens after the woman becomes postmenopausal.</li></ul></li><li><strong>For postmenopausal women, </strong>monthly or 3-monthly cyclical regimens, or a continuous combined regimen may be used.<ul><li>A continuous combined regimen may be preferred as it does not produce withdrawal bleeding.</li><li>Note: a continuous combined regimen may produce irregular bleeding or spotting for the first 4–6 months of treatment. If bleeding persists beyond 6 months, becomes heavier, or occurs after a spell of amenorrhoea, endometrial pathology should be excluded. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gynaecological-cancers-recognition-referral/\">Gynaecological cancers - recognition and referral</a> for more information.</li></ul></li><li><strong>Vaginal oestrogen therapy regimens depend on the vaginal preparation used:</strong><ul><li>One vaginal tablet daily for 2 weeks, then reduced to one vaginal tablet twice weekly.</li><li>One applicatorful daily for 3–4 weeks, then reduced to one applicatorful twice weekly, to be applied at bedtime, for cream and gel preparations.</li><li>One pessary daily for 3 weeks, then reduced to one pessary twice weekly, to be inserted at bedtime.</li><li>One vaginal ring inserted into the upper third of vagina and worn continuously, to be replaced at 3 months. Maximum duration of continuous treatment is 2 years.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Rees, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Ayres, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Joint Formulary Committee, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stephens, 2020</a>]</p><!-- end field 9abe46d5-c907-418b-9054-5a8613bf23ce --><!-- end item e0ea5cee-1ae5-4979-83d9-5f32d29dfa32 -->","subChapters":[]},{"id":"b0b23ccd-7d62-54d4-b158-a13f58ec3ab6","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 55c294f3-8edf-4126-877e-dc457d5f85f1 --><h3>Adverse effects</h3><!-- end field 55c294f3-8edf-4126-877e-dc457d5f85f1 -->","summary":"","htmlStringContent":"<!-- begin item f5fcd132-8bfe-42ad-9226-9906d5f0820d --><!-- begin field a525f5e2-57e4-42f7-a176-a6b601339452 --><p><strong>Hormone replacement therapy (HRT) may cause a variety of adverse effects.</strong></p><ul><li><strong>Oestrogen-related adverse effects</strong> include [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Joint Formulary Committee, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stephens, 2020</a>]:<ul><li>Fluid retention, bloating, breast tenderness or enlargement, nausea, headaches, leg cramps, and dyspepsia.</li></ul></li><li><strong>Progestogen-related adverse effects</strong> include [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Rees, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Joint Formulary Committee, 2020</a>]:<ul><li>Fluid retention, breast tenderness, headaches or migraine, mood swings, premenstrual syndrome-like symptoms, depression, acne vulgaris, lower abdominal pain, and back pain. They tend to occur in a cyclical pattern during the progestogen phase of cyclical HRT.</li></ul></li><li><strong>Vaginal bleeding problems</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Rees, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Joint Formulary Committee, 2020</a>]<ul><li>Unscheduled vaginal bleeding is a common adverse effect of HRT within the first 3 months of treatment.</li><li>Monthly cyclical regimens should produce regular withdrawal bleeding towards the end of the progestogen phase.</li><li>Continuous combined HRT commonly produces irregular breakthrough bleeding or spotting in the first 4–6 months of treatment. If bleeding persists beyond 6 months, becomes heavier, or occurs after a spell of amenorrhoea, endometrial pathology should be excluded. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gynaecological-cancers-recognition-referral/\">Gynaecological cancers - recognition and referral</a> for more information.<ul><li>Unpredictable or unexpected bleeding may also be due to non-adherence with treatment, drug interactions, or a gastrointestinal disorder (which may affect drug absorption).</li></ul></li><li>If serious gynaecological pathology has been excluded, altering the progestogen part of the regimen may improve bleeding problems. Options include:<ul><li>Increasing the <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#regimen\">duration</a> or dose of the progestogen, or changing the <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#choice-of-hormone\">type</a> of progestogen, for example switching to the levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena<sup>®</sup>) combined with an oral or transdermal oestrogen preparation.</li></ul></li></ul></li></ul><!-- end field a525f5e2-57e4-42f7-a176-a6b601339452 --><!-- end item f5fcd132-8bfe-42ad-9226-9906d5f0820d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}